TapewireFind a company

person · Reporting owner

BIRD JEFFREY W

Disclosed activity across 7 companies

Tapewire entity
147988
SEC CIK
0001250409

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Everpure, Inc.PSTG · Entity 314010% ownerJanuary 31, 2018February 23, 2018
Mattersight CorpMATR · Entity 16410710% ownerMay 31, 2017June 02, 2017
Molecular Templates, Inc.THLD · Entity 85987DirectorMay 31, 2017June 02, 2017
PORTOLA PHARMACEUTICALS INCPTLA · Entity 147987DirectorJuly 02, 2020July 07, 2020
Venus Concept Inc.HAIR · Entity 55304DirectorJune 13, 2018June 15, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Everpure, Inc.

Report date January 31, 2018 · Filed February 23, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Ltd Partnership (NEST)499,478 Reported balance After 2018-01-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-01-01 · Gift · Disposed 0 · Balance 499,478

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F2: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein.

F3: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityDirect227,244 Reported balance Holding disclosure · report date 2018-01-31 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance 227,244

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Irrevocable Trust (BICT)85,404 Reported balance Holding disclosure · report date 2018-01-31 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance 85,404

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F4: Shares held by an irrevocable trust for the benefit of the reporting person's children, of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.

Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Ltd Liability Company (SHA)1,024,538 Reported balance Holding disclosure · report date 2018-01-31 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance 1,024,538

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F5: Shares held by Sutter Hill Associates, LLC ("SHA"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHA, and the reporting person is a trustee of a trust which is a member of SHA. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Ltd Liability Company (SHM)77,100 Reported balance Holding disclosure · report date 2018-01-31 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance 77,100

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F6: Shares held by Sutter Hill Management Company, L.L.C ("SHM"). SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Ltd Partnership (SHV As Nominee)318,750 Reported balance Holding disclosure · report date 2018-01-31 · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · Balance 318,750

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F7: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Ltd Partnership (SHV)17,102,128 Reported balance Holding disclosure · report date 2018-01-31 · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · Balance 17,102,128

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F8: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Class B Common StockSEC Table II · derivative / convertible securityIndirectBy Trust (Trustees)1,281,244 Reported balance Holding disclosure · report date 2018-01-31 · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · Balance 1,281,244

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F9: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.

F2: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein.

F3: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F4: Shares held by an irrevocable trust for the benefit of the reporting person's children, of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.

F5: Shares held by Sutter Hill Associates, LLC ("SHA"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHA, and the reporting person is a trustee of a trust which is a member of SHA. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F6: Shares held by Sutter Hill Management Company, L.L.C ("SHM"). SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F7: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F8: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F9: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Mattersight Corp

Report date May 31, 2017 · Filed June 02, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (NEST)108,557 Reported balance After 2017-06-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2017-06-01 · Purchase · Acquired 16,189 · Balance 108,557

F1: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 16,189 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F2: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (SHV)1,056,194 Last balance in matching sequence After 2017-06-01 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2017-05-31 · Other · Disposed 271,391 · Balance 852,651

F3: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 271,391 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").

F4: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Row 3 · 2017-06-01 · Purchase · Acquired 203,543 · Balance 1,056,194

F5: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 203,543 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F4: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Trust (Trustees)71,840 Reported balance Holding disclosure · report date 2017-05-31 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 71,840

F6: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 16,189 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F2: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F3: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 271,391 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").

F4: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F5: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 203,543 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F6: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Molecular Templates, Inc.

Report date May 31, 2017 · Filed June 02, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (SHV)3,940,573 Last balance in matching sequence After 2017-06-01 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2017-05-31 · Other · Disposed 630,770 · Balance 3,467,496

F1: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 630,770 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").

F2: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Row 2 · 2017-06-01 · Purchase · Acquired 473,077 · Balance 3,940,573

F3: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 473,077 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F2: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Trust377,782 Reported balance After 2017-06-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2017-06-01 · Purchase · Acquired 37,626 · Balance 377,782

F4: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 37,626 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect919 Reported balance Holding disclosure · report date 2017-05-31 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 919

Filing footnotes · ownership attribution and instrument terms

F1: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 630,770 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").

F2: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F3: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 473,077 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F4: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 37,626 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.

F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 07, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-07-02 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2020-07-02 · Disposition to issuer · Disposed 20,475 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Liability Company (SHM)0 Reported balance After 2020-07-02 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2020-07-02 · Disposition to issuer · Disposed 10,007 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F3: Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (NEST)0 Reported balance After 2020-07-02 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2020-07-02 · Disposition to issuer · Disposed 45,402 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F4: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Trust (Trustees)0 Reported balance After 2020-07-02 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2020-07-02 · Disposition to issuer · Disposed 458,569 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.19 · Expires 2026-06-01Direct0 Reported balance After 2020-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-07-02 · Disposition to issuer · Disposed 6,000 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.74 · Expires 2023-06-04Direct0 Reported balance After 2020-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-07-02 · Disposition to issuer · Disposed 14,101 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.81 · Expires 2028-06-07Direct0 Reported balance After 2020-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2020-07-02 · Disposition to issuer · Disposed 6,000 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2029-06-12Direct0 Reported balance After 2020-07-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2020-07-02 · Disposition to issuer · Disposed 6,991 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-12Direct0 Reported balance After 2020-07-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0

F7: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.39 · Expires 2025-06-16Direct0 Reported balance After 2020-07-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2020-07-02 · Disposition to issuer · Disposed 10,000 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.06 · Expires 2027-06-16Direct0 Reported balance After 2020-07-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2020-07-02 · Disposition to issuer · Disposed 6,000 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.19 · Expires 2024-06-27Direct0 Reported balance After 2020-07-02 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2020-07-02 · Disposition to issuer · Disposed 10,000 · Balance 0

F6: In connection with the Merger, these options were canceled without payment.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

F3: Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F4: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein.

F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

F6: In connection with the Merger, these options were canceled without payment.

F7: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

Venus Concept Inc.

Report date June 13, 2018 · Filed June 15, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2028-06-13Direct13,708 Reported balance After 2018-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-06-13 · Grant · Acquired 13,708 · Balance 13,708

F1: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forty Seven, Inc.

Report date April 07, 2020 · Filed April 07, 2020

Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (BBV)0 Reported balance After 2020-04-07 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2020-04-07 · Disposition to issuer · Disposed 562,500 · Balance 0

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F2: Shares held by Bluebird Ventures I, L.P. of which the Reporting Person is the managing director of the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Trust0 Reported balance After 2020-04-07 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2020-04-07 · Disposition to issuer · Disposed 233,564 · Balance 0

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F3: Shares held by the Jeffrey W. and Christina R. Bird Trust of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (NEST)0 Reported balance After 2020-04-07 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2020-04-07 · Disposition to issuer · Disposed 215,375 · Balance 0

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F4: Shares held by NestEgg Holdings, LP of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy LLC (SHM)0 Reported balance After 2020-04-07 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2020-04-07 · Disposition to issuer · Disposed 6,596 · Balance 0

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F5: Shares held by SHM Investments, LLC, a limited liability company of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26Direct0 Reported balance After 2020-04-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-04-07 · Disposition to issuer · Disposed 20,645 · Balance 0

F6: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2029-06-11Direct0 Reported balance After 2020-04-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-04-07 · Disposition to issuer · Disposed 10,322 · Balance 0

F7: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F2: Shares held by Bluebird Ventures I, L.P. of which the Reporting Person is the managing director of the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

F3: Shares held by the Jeffrey W. and Christina R. Bird Trust of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

F4: Shares held by NestEgg Holdings, LP of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

F5: Shares held by SHM Investments, LLC, a limited liability company of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

F6: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F7: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Yext, Inc.

Report date December 01, 2017 · Filed December 05, 2017

Section 16 reporting ended · disclosed 2017-12-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Ltd Liability Company (SHM)78,140 Reported balance After 2017-12-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2017-12-01 · Other · Acquired 78,140 · Balance 78,140

F1: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV").

F2: Shares held by SHM. SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (SHV As Nominee)323,049 Reported balance After 2017-12-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2017-12-01 · Other · Acquired 323,049 · Balance 323,049

F3: Represents the retention of shares by SHV, in connection with the distribution described below, for the benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV.

F4: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (SHV)0 Reported balance After 2017-12-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2017-12-01 · Other · Disposed 8,614,633 · Balance 0

F5: Effective December 1, 2017, SHV effected a pro rata distribution of 8,614,633 shares of Common Stock to its limited partners and its general partner for no additional consideration, of which 6,460,975 shares were distributed to the limited partners and 2,153,658 shares, representing the general partner's interest in the distribution, were retained by SHV and are now being held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner. SHV has no pecuniary interest in such retained shares.

F6: Excludes shares of Common Stock held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner of SHV.

F7: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Irrevocable Trust (BICT)35,602 Reported balance Holding disclosure · report date 2017-12-01 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 35,602

F8: Shares held by an irrevocable trust for the benefit of the reporting person's children of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.

Common StockSEC Table I · non-derivativeIndirectBy Ltd Partnership (NEST)377,280 Reported balance Holding disclosure · report date 2017-12-01 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 377,280

F9: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Trust311,959 Reported balance Holding disclosure · report date 2017-12-01 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 311,959

F10: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV").

F2: Shares held by SHM. SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F3: Represents the retention of shares by SHV, in connection with the distribution described below, for the benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV.

F4: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F5: Effective December 1, 2017, SHV effected a pro rata distribution of 8,614,633 shares of Common Stock to its limited partners and its general partner for no additional consideration, of which 6,460,975 shares were distributed to the limited partners and 2,153,658 shares, representing the general partner's interest in the distribution, were retained by SHV and are now being held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner. SHV has no pecuniary interest in such retained shares.

F6: Excludes shares of Common Stock held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner of SHV.

F7: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F8: Shares held by an irrevocable trust for the benefit of the reporting person's children of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.

F9: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

F10: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $29.19 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 12

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2024-06-27

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Strike: $35.06 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 11

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2027-06-16

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $44.39 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 10

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2025-06-16

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 11,377 Not disclosed Strike: $17.94 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 9

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,377 shares

Expires 2030-06-12

F7 · price: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F7 · derivative.exercise_date: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 6,991 Not disclosed Strike: $26.09 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 8

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,991 shares

Expires 2029-06-12

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Strike: $42.81 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 7

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2028-06-07

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 14,101 Not disclosed Strike: $19.74 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 6

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,101 shares

Expires 2023-06-04

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Strike: $24.19 Not disclosed
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 5

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2026-06-01

F6 · price: In connection with the Merger, these options were canceled without payment.

F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerCommon Stock 458,569 $18.00 $8,254,242.00
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 4

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust (Trustees)

Disclosed balance after: 0

F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F5 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerCommon Stock 45,402 $18.00 $817,236.00
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 3

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 0

F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerCommon Stock 10,007 $18.00 $180,126.00
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 2

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Liability Company (SHM)

Disclosed balance after: 0

F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F3 · ownership.nature: Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2020 Filed Jul 7, 2020 15:39 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 Disposition to issuerCommon Stock 20,475 $18.00 $368,550.00
Disclosure

SEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 17:01 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 GrantStock Option (Right to Buy) · Derivative 11,377 $0.00 Strike: $17.94 $0.00
Disclosure

SEC source: 0001225208-20-009041 · doc4.xml · derivative · entry 5

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,377

Underlying: Common Stock · 11,377 shares

Expires 2030-06-12

F6 · derivative.exercise_date: The option shares shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
June 12, 2020 Filed Jun 16, 2020 17:01 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 GrantCommon Stock 7,281 $0.00 $0.00
Disclosure

SEC source: 0001225208-20-009041 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,475

F1 · price: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2021, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
April 07, 2020 Filed Apr 7, 2020 13:25 UTC Forty Seven, Inc. FTSV · Entity 16035 Disposition to issuerStock Option (right to buy) · Derivative 10,322 Not disclosed Strike: $10.81 Not disclosed
Disclosure

SEC source: 0001209191-20-023727 · doc4.xml · derivative · entry 6

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,322 shares

Expires 2029-06-11

F7 · price: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F7 · derivative.exercise_date: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Read SEC document
April 07, 2020 Filed Apr 7, 2020 13:25 UTC Forty Seven, Inc. FTSV · Entity 16035 Disposition to issuerStock Option (right to buy) · Derivative 20,645 Not disclosed Strike: $8.76 Not disclosed
Disclosure

SEC source: 0001209191-20-023727 · doc4.xml · derivative · entry 5

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,645 shares

Expires 2028-04-26

F6 · price: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

F6 · derivative.exercise_date: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.

Read SEC document
April 07, 2020 Filed Apr 7, 2020 13:25 UTC Forty Seven, Inc. FTSV · Entity 16035 Disposition to issuerCommon Stock 6,596 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 4

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By LLC (SHM)

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F5 · ownership.nature: Shares held by SHM Investments, LLC, a limited liability company of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Read SEC document
April 07, 2020 Filed Apr 7, 2020 13:25 UTC Forty Seven, Inc. FTSV · Entity 16035 Disposition to issuerCommon Stock 215,375 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 3

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F4 · ownership.nature: Shares held by NestEgg Holdings, LP of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Read SEC document
April 07, 2020 Filed Apr 7, 2020 13:25 UTC Forty Seven, Inc. FTSV · Entity 16035 Disposition to issuerCommon Stock 233,564 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 2

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F3 · ownership.nature: Shares held by the Jeffrey W. and Christina R. Bird Trust of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Read SEC document
April 07, 2020 Filed Apr 7, 2020 13:25 UTC Forty Seven, Inc. FTSV · Entity 16035 Disposition to issuerCommon Stock 562,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (BBV)

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

F2 · ownership.nature: Shares held by Bluebird Ventures I, L.P. of which the Reporting Person is the managing director of the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

Read SEC document
September 03, 2019 Filed Sep 3, 2019 18:04 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 OtherCommon Stock 9,516 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-012058 · doc4.xml · nonDerivative · entry 3

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust (Trustees)

Disclosed balance after: 458,569

F5 · kind: Represents the receipt of shares in a pro rata distribution effective September 3, 2019, for no additional consideration, from SHV.

F5 · shares: Represents the receipt of shares in a pro rata distribution effective September 3, 2019, for no additional consideration, from SHV.

F5 · price: Represents the receipt of shares in a pro rata distribution effective September 3, 2019, for no additional consideration, from SHV.

F6 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Read SEC document
September 03, 2019 Filed Sep 3, 2019 18:04 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 OtherCommon Stock 921,610 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-012058 · doc4.xml · nonDerivative · entry 2

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 0

F3 · kind: Effective September 3, 2019, SHV effected a pro rata distribution to its limited partners and its general partner for no additional consideration.

F3 · shares: Effective September 3, 2019, SHV effected a pro rata distribution to its limited partners and its general partner for no additional consideration.

F3 · price: Effective September 3, 2019, SHV effected a pro rata distribution to its limited partners and its general partner for no additional consideration.

F4 · ownership.nature: Shares held by SHV. The reporting person is a managing director of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
September 03, 2019 Filed Sep 3, 2019 18:04 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 OtherCommon Stock 10,007 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-012058 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Liability Company (SHM)

Disclosed balance after: 10,007

F1 · kind: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV").

F1 · shares: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV").

F1 · price: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV").

F2 · ownership.nature: Shares held by SHM. SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 22, 2019 Filed Jul 24, 2019 16:06 UTC Forty Seven, Inc. FTSV · Entity 16035 PurchaseCommon Stock 187,500 $8.00 $1,500,000.00
Disclosure

SEC source: 0001225208-19-010430 · doc4.xml · nonDerivative · entry 2

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 192,419

F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 22, 2019 Filed Jul 24, 2019 16:06 UTC Forty Seven, Inc. FTSV · Entity 16035 PurchaseCommon Stock 562,500 $8.00 $4,500,000.00
Disclosure

SEC source: 0001225208-19-010430 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (BBV)

Disclosed balance after: 562,500

F1 · ownership.nature: Shares held by Bluebird Ventures I, L.P. of which the reporting person is the managing director of the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
June 13, 2019 Filed Jun 17, 2019 20:06 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 GrantStock Option (Right to Buy) · Derivative 6,991 $0.00 Strike: $26.09 $0.00
Disclosure

SEC source: 0001225208-19-009340 · doc4.xml · derivative · entry 5

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,991

Underlying: Common Stock · 6,991 shares

Expires 2029-06-12

F6 · derivative.exercise_date: The option shares shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
June 13, 2019 Filed Jun 17, 2019 20:06 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 GrantCommon Stock 4,194 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-009340 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,194

F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2020, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F1 · price: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2020, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
June 12, 2019 Filed Jun 14, 2019 18:54 UTC Forty Seven, Inc. FTSV · Entity 16035 GrantStock Option (right to buy) · Derivative 10,322 $0.00 Strike: $10.81 $0.00
Disclosure

SEC source: 0001225208-19-009285 · doc4.xml · derivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,322

Underlying: Common Stock · 10,322 shares

Expires 2029-06-11

F1 · derivative.exercise_date: The shares subject to the option vest on the one-year anniversary of the grant date, subject to reporting person's continuous service on such date.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
August 23, 2018 Filed Aug 23, 2018 19:32 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 PurchaseCommon Stock 50,355 $26.65 $1,341,809.69
Disclosure

SEC source: 0001225208-18-012883 · doc4.xml · nonDerivative · entry 3

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust (Trustees)

Disclosed balance after: 449,053

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.41 to $26.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Read SEC document
August 22, 2018 Filed Aug 23, 2018 19:32 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 PurchaseCommon Stock 202,082 $26.09 $5,273,006.46
Disclosure

SEC source: 0001225208-18-012883 · doc4.xml · nonDerivative · entry 2

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust (Trustees)

Disclosed balance after: 398,698

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.89 to $26.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Read SEC document
August 21, 2018 Filed Aug 23, 2018 19:32 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 PurchaseCommon Stock 137,563 $25.17 $3,462,570.76
Disclosure

SEC source: 0001225208-18-012883 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust (Trustees)

Disclosed balance after: 196,616

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries A-1 Preferred Stock · Derivative 667 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 16

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F4 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries B Preferred Stock · Derivative 945,326 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 15

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 0

Underlying: Common Stock · 945,326 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries A-2 Preferred Stock · Derivative 774,165 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 14

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 0

Underlying: Common Stock · 774,165 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries A-1 Preferred Stock · Derivative 1,052,146 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 13

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 0

Underlying: Common Stock · 1,052,146 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries B Preferred Stock · Derivative 73,686 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 12

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 0

Underlying: Common Stock · 73,686 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries A-2 Preferred Stock · Derivative 73,159 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 11

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 0

Underlying: Common Stock · 73,159 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionSeries A-1 Preferred Stock · Derivative 68,530 Not disclosed Not disclosed
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 10

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 0

Underlying: Common Stock · 68,530 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 667 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 9

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 4,919

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F4 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 PurchaseCommon Stock 4,252 $16.00 $68,032.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 8

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 4,252

F4 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 PurchaseCommon Stock 134,735 $16.00 $2,155,760.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 7

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 2,906,372

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 774,165 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 6

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 2,771,637

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 945,326 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 5

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 1,997,472

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 1,052,146 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 4

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (SHV)

Disclosed balance after: 1,052,146

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 68,530 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 3

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 215,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 73,159 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 2

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 146,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:42 UTC Forty Seven, Inc. FTSV · Entity 16035 ConversionCommon Stock 73,686 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Ltd Partnership (NEST)

Disclosed balance after: 73,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.

Read SEC document
June 13, 2018 Filed Jun 15, 2018 20:05 UTC Venus Concept Inc. HAIR · Entity 55304 GrantStock Option (Right to Buy) · Derivative 13,708 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-18-016754 · doc4.xml · derivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,708

Underlying: Common Stock · 13,708 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 17:01 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 GrantStock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $42.81 $0.00
Disclosure

SEC source: 0001225208-18-010489 · doc4.xml · derivative · entry 5

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2028-06-07

F6 · derivative.exercise_date: The option shares shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 17:01 UTC PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 GrantCommon Stock 3,000 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-010489 · doc4.xml · nonDerivative · entry 1

BIRD JEFFREY W · CIK 0001250409 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2019, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date.

F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.